Renal risk reflects how kidney function affects supplement safety, especially for high burden compounds.
Why it matters
Kidney capacity influences how fluid load, mineral clearance, and protein-heavy protocols are tolerated.
CKD-stage-aware caution
For reduced kidney function, recommendations may be more conservative or paused depending on severity.
Avoid broad stack scaling and prioritize clinician coordination.
Hydration and lab triggers
- rising creatinine trend, edema, reduced urine output, or unexplained fatigue should trigger stop-and-review
- hydration consistency is a required context variable before dose increases
- monitor electrolyte shifts when combining protein-heavy and mineral-heavy stacks
High-caution compounds
- high-dose creatine in severe CKD contexts
- aggressive mineral clustering
- protein-dense stacked protocols without renal context
Practical action step
Before increasing dose, log hydration and current kidney-related lab context for 3–5 days and review with clinician support.
Uncertainty and limits
- Evidence is limited on safe upper boundaries for many compounds in moderate-to-advanced CKD.
- Evidence is limited on long-term kidney-safe timing strategies in non-prescription stacks.
Cross-site references
How this appears in Unfair
Unfair increases caution for renal-risk profiles by suppressing escalation and emphasizing lower complexity plans.
Clinical safety note
If renal warning signs appear, pause relevant stacks and get clinical evaluation before resuming.